Arena Pharmaceuticals, Inc. ARNA announced today that the Office of the Federal Register filed for public
inspection the US Drug Enforcement Administration's (DEA) final rule placing
BELVIQ ^ (pronounced BEL-VEEK) into Schedule IV of the Controlled Substances
Act. The scheduling designation will be effective 30 days after tomorrow's
expected publication in the Federal Register. Following the effective date,
BELVIQ will be available to patients in the United States by prescription, and
Arena will receive $65 million in milestone payments from Eisai Inc. under
their marketing and supply agreement.
BELVIQ is approved for use as an adjunct to a reduced-calorie diet and
increased physical activity for chronic weight management in adult patients
with an initial body mass index (BMI) of 30 kg/m^2 or greater (obese), or 27
kg/m^2 or greater (overweight) in the presence of at least one weight-related
comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes). The
indication includes the following limitations of use: The safety and efficacy
of coadministration of BELVIQ with other products intended for weight loss and
the effect of BELVIQ on cardiovascular morbidity and mortality have not been
established.
"We are thrilled that BELVIQ will soon be available in the United States as a
new treatment option for the medical management of patients who are overweight
with a comorbidity or obese," said Jack Lief, Arena's President and Chief
Executive Officer.
Eisai is responsible for the marketing and distribution of BELVIQ in the
United States. Arena manufactures BELVIQ at its facility in Switzerland, and
sells finished commercial product to Eisai for a purchase price starting at
31.5% of Eisai's annual net product sales. The purchase price increases on a
tiered basis up to 36.5% on the portion of annual net product sales exceeding
$750 million. Arena is also eligible to receive $1.16 billion in purchase
price adjustment payments based on annual net sales levels of BELVIQ.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in